Aquestive Therapeutics Inc (NASDAQ:AQST) saw a notable insider stock move earlier this month when President and CEO Daniel Barber executed a sale of company shares, according to a Form 4 filed with the Securities and Exchange Commission.
On March 10, 2026, Barber sold 180,677 shares of common stock at a weighted average price of $4.173 per share. Individual sale prices in the transaction ranged from $4.17 to $4.33, producing total proceeds of $753,965.
The filing also documents related activity a day earlier. On March 9, 2026, Barber acquired 262,000 shares of common stock with a reported value of $0 and was granted 523,000 Non-Qualified Stock Options, carrying an exercise price of $4.29.
After completing the March 10 sale, Barber directly holds 1,004,753 shares of Aquestive Therapeutics common stock.
Context and market pricing
The insider sale came as AQST was trading at $4.27, a price close to Barber's weighted sale price. Analysis from InvestingPro cited in the filing indicates the stock appears overvalued relative to its Fair Value estimate and placed AQST on its Most Overvalued list. The platform's Pro Research Report also highlights the share price's volatility: a 62% increase over the past year contrasted with a 34% decline year-to-date.
Company financial and regulatory updates
Aquestive's fourth-quarter 2025 results were included in the recent disclosures. The company reported a net loss of $0.26 per share, wider than analyst expectations of a $0.13 loss per share. Revenues for the quarter totaled $13 million, slightly under the $13.34 million analysts had forecast.
Separately, Citizens maintained its Market Outperform rating on Aquestive with a $10.00 price target. The firm noted a clear path for the company's planned re-submission to the U.S. Food and Drug Administration and flagged an upcoming meeting intended to clarify remaining steps. Aquestive reaffirmed its timeline to re-submit the Anaphylm NDA in the third quarter of 2026.
What the filings show
The sequence of transactions - share acquisitions and option grants on March 9, followed by a significant sale on March 10 - are recorded in the SEC Form 4 and leave Barber with just over one million shares directly held. The filings provide a snapshot of insider positioning as the company works through regulatory milestones and digests a quarterly result that missed consensus estimates.
Observers will note the convergence of insider activity, a recent earnings miss, analyst commentary on the regulatory pathway and third-party valuation assessments as relevant factors for investors assessing AQST's near-term outlook.